Heat Biologics to Present at the 2018 BIO Investor Forum

DURHAM, NC / ACCESSWIRE / October 10, 2018 / Heat Biologics, Inc. HTBX, a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced that the company is scheduled to present at the 2018 BIO Investor Forum. The Forum will be held on October 17^th and 18^th at the Westin St. Francis Hotel in San Francisco, California.

Jeff Wolf, Founder and Chief Executive Officer of Heat Biologics, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the forum.

Presentation Date: Wednesday, October 17, 2018
Time: 3:45 PM, PT
Location: Elizabethan A Room

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Our ComPACT technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We are currently enrolling patients in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. We also have numerous pre-clinical programs at various stages of development. For more information, please visit www.heatbio.com.

Media and Investor Relations Contact:

David Waldman
+1 919 289 4017
investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.